Drug Trial Radar · NCT06682793
A Study to Evaluate the Safety and Efficacy of A2B395, an Allogeneic Logic-gated CAR T, in Participants With Solid Tumors That Express EGFR and Have Lost HLA-A*02 Expression
Last checked: Nov 20, 2026Latest source record: Nov 18, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
240
Planned (sponsor's estimate)
Start
May 22, 2025
Primary completion
Mar 31, 2029
Study completion Mar 31, 2030
Sponsor
- Lead sponsor
- A2 Biotherapeutics Inc.Industry
- Sponsor type
- Industry
- First posted
- Nov 12, 2024
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The goal of this study is to test A2B395, an allogeneic logic-gated Tmod™ CAR T-cell product in subjects with solid tumors including colorectal cancer (CRC), non-small cell lung cancer (NSCLC), head and neck squamous cell carcinoma (HNSCC), triple-negative breast cancer (TNBC), renal cell carcinoma (RCC) and other solid tumors that express EGFR and have lost HLA-A\*02 expression. The main questions this study aims to answer are: * Phase 1: What is the recommended dose of A2B395 that is safe for patients * Phase 2: Does the recommended dose of A2B395 kill the solid tumor cells and protect the patient's healthy cells Participants will be required to perform study procedures and assessments, and will also receive the following study treatments: * Enrollment in BASECAMP-1 (NCT04981119) * Preconditioning lymphodepletion (PCLD) regimen * A2B395 Tmod CAR T cells at the assigned dose
Conditions
- Solid Tumor, Adult
- Colorectal Cancer
- Non-Small Cell Lung
- NSCLC (Non-small Cell Lung Cancer)
- Cancer
- Colon Cancer
- Rectal Cancer
- Lung Cancer
- CRC
- Head and Neck Squamous Cell Cancer
- HNSCC
- Renal Cell Carcinoma
- RCC
- Kidney Cancer
- Triple Negative Breast Cancer
- TNBC
- Colorectal Adenocarcinoma
Interventions
A2B395Biological
Allogeneic logic-gated Tmod CAR T cells
xT CDx with HLA-LOH assayDiagnostic test
An investigational next generation sequencing (NGS) in vitro diagnostic (IVD) medical device
Primary outcomes
What the sponsor says the trial is designed to measure.
- Phase 1: Rate of adverse events and dose limiting toxicities (DLTs) by dose levelTime frame: From the time of Informed consent until 24 months (2 years) post A2B395 infusion
- Phase 1: Recommended phase 2 dose (RP2D)Time frame: 28 days post A2B395 infusion
- Phase 2: The overall response rate (ORR) for patientsTime frame: 24 months post A2B395 infusion
Locations
13 sites in 1 country. Site status is shown where the registry gives one.
Banner MD Anderson Cancer Center
Gilbert, Arizona
Mayo Arizona
Phoenix, Arizona
UCSD Moores Cancer Center
La Jolla, California
UCLA Medical Center
Los Angeles, California
Stanford University
Palo Alto, California
Mayo Clinic
Jacksonville, Florida
Moffitt Cancer Center
Tampa, Florida
Mayo Clinic
Rochester, Minnesota
Washington University
St Louis, Missouri
NYU Langone Health
New York, New York
The Ohio State University
Columbus, Ohio
Vanderbilt-Ingram Cancer Center
Nashville, Tennessee
Fred Hutch Cancer Center
Seattle, Washington
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.